<DOC>
	<DOCNO>NCT01283503</DOCNO>
	<brief_summary>In study , BKM120 administer adult patient advance solid tumor whose disease progress despite standard therapy standard therapy exist . The trial confirm safety tolerability determine maximum tolerate dose ( MTD ) BKM120 Japanese patient .</brief_summary>
	<brief_title>A Study BKM120 Adult Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Patients histologically confirm , advance unresectable solid tumor progress ( able tolerate ) standard therapy standard anticancer therapy exist . 2 . At least one measurable nonmeasurable lesion define RECIST guideline solid tumor . 3 . Age ≥ 20 year 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG P.S . ) ≤ 2 5 . Life expectancy ≥ 12 week 6 . Patients must laboratory value 1 . Patients history primary central nervous system tumor brain metastasis signs/symptoms attribute brain metastasis assess radiologic imaging rule presence brain metastases 2 . Prior treatment PI3K inhibitor 3 . Patients peripheral neuropathy ≥ CTCAE grade 2 4 . Patients unresolved diarrhea ≥ CTCAE grade 2 5 . Women childbearing potential pregnant breast feeding . Men woman reproductive potential sign inform consent birth control . Barrier contraceptives must use throughout trial six month end treatment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PI3K ,</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>